Abstract

The purpose of this Core is to provide the following services that will be utilized by the research projects included in this Program Project:
Specific Aim 1. To provide biostatistical collaboration for clinical research protocols. This includes all aspects of design, conduct, analysis and reporting of the clinical protocols, and direction of data processing and quality control assurance.
Specific Aim 2. To provide biostatistical collaboration for animal and laboratory research studies. This includes all aspects of design, conduct, analysis and reporting of such studies, including the coordination of laboratory results with parameters and outcomes from the clinical studies.
Specific Aim 3. To supervise the data processing and data quality assurance, and to coordinate the efforts of the data coordinator and those of the data analyst in maintaining an accurate computerized database.
Specific Aim 4. To provide computing resources for data processing, forms design, statistical analysis, standardized reporting and quality control.
Specific Aim 5. To provide bioinformatic support for analysis of high throughput transcriptional and genomic studies.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA078378-15
Application #
8650272
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
15
Fiscal Year
2014
Total Cost
$195,260
Indirect Cost
$118,280

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Tai, Yu-Tzu; Lin, Liang; Xing, Lijie et al. (2018) APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia :
Bae, J; Hideshima, T; Zhang, G L et al. (2018) Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma. Leukemia 32:752-764
Pyzer, Athalia Rachel; Stroopinsky, Dina; Rajabi, Hasan et al. (2017) MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood 129:1791-1801
Cholujova, Danka; Bujnakova, Zdenka; Dutkova, Erika et al. (2017) Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol 179:756-771
Yin, Li; Tagde, Ashujit; Gali, Reddy et al. (2017) MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol 178:914-926
Harada, T; Ohguchi, H; Grondin, Y et al. (2017) HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications. Leukemia 31:2670-2677
Hideshima, Teru; Cottini, Francesca; Nozawa, Yoshihisa et al. (2017) p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood 129:1308-1319
Ohguchi, H; Harada, T; Sagawa, M et al. (2017) KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival. Leukemia 31:2661-2669
Feng, Xiaoyan; Zhang, Li; Acharya, Chirag et al. (2017) Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. Clin Cancer Res 23:4290-4300
Bar-Natan, Michal; Stroopinsky, Dina; Luptakova, Katarina et al. (2017) Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol 176:929-938

Showing the most recent 10 out of 270 publications